bioRxivCancer Biology
Prevention and reversion of pancreatic tumorigenesis through a differentiation-based mechanism
N. M. Krah, D. Yugawa, J. Straley, C. V. E. Wright, R. J. MacDonald, L. C. Murtaugh
Abstract
Activating mutations in Kras are nearly ubiquitous in human pancreatic cancer and initiate precancerous pancreatic intraepithelial neoplasia (PanINs) when induced in adult murine acinar cells. PanINs normally take months to form, but can be rapidly induced by genetic deletion of acinar cell differentiation factors such as Ptf1a, suggesting that loss of mature cell identity is a rate-limiting step in pancreatic tumor initiation. Using a novel genetic mouse model that allows for independent control of oncogenic Kras and Ptf1a expression, we demonstrate that maintained activity of Ptf1a is sufficient to eliminate Kras-driven tumorigenesis, even in the presence of tumor-promoting inflammation. Furthermore, reintroduction of Ptf1a into established PanINs reverts their phenotype in vivo. Our results suggest that reactivation of an endogenous differentiation program can prevent and reverse oncogenesis in cells harboring tumor driving mutations, thus introducing a novel paradigm for solid tumor prevention and treatment.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of p53 tumor suppression function drives invasion and genomic instability in models of murine pancreatic cancer
C. Tonelli, A. Deschenes, … D. A. Tuveson·bioRxiv·Dec 31, 2021
- Loss of Activating Transcription Factor 3 prevents KRAS-mediated pancreatic cancer
- Ductal pancreatic cancer interception by FGFR2 abrogation
Claudia Tonelli, Astrid Deschênes, … David Arthur Tuveson·Cancer ResearchPeer-reviewed·Apr 2, 2025
- Mouse models for pancreatic ductal adenocarcinoma are affected by the cre-driver used to promote KRASG12D activation.
F. Mousavi, J. Thompson, … F. Bednar·bioRxiv·Sep 12, 2023
- Drug-Induced p53 Activation Limits Pancreatic Cancer Initiation
Jennifer J. Twardowski, Thomas I. Heist, … Stephano S. Mello·bioRxiv·May 29, 2024
- Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis
Adrien Grimont, David J. Falvo, … Rohit Chandwani·Developmental CellPeer-reviewed·Jul 21, 2026